Functional Concept – Page 4

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

1 week ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles

2 weeks ago talkbio0Tagged brain volume, calcium, Disability, Multiple Sclerosis, Progressive, vidofludimus

Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability

Entrada tightens focus on Duchenne, axes 20% of staff

2 weeks ago talkbio0Tagged ENTR-601, exon, Muscular Dystrophy, Duchenne, Study on Hold, United States Food and Drug Administration

Duchenne muscular dystrophy (DMD), workforce reduction, ENTR-601-44, ENTR-601-45, FDA clinical hold, exon skipping therapy

AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap

2 weeks ago talkbio0Tagged AstraZeneca, Faslodex, Malignant neoplasm of breast, Television, Truqap

Truqap, AstraZeneca, Television, Faslodex, Malignant neoplasm of breast

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

2 weeks ago talkbio0Tagged Accelerated, Agencies, Artificial Intelligence, Califf, Contraceptives, Oral, Infrequent, RIFs, United States Food and Drug Administration, Unspecified Abortion

United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies

Regeneron crumples under the weight of missed Eylea expectations

2 weeks ago talkbio0Tagged decline, earnings, Eylea, Regeneron, Sales - occupational activity, United States Food and Drug Administration

Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity

Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring

2 weeks ago talkbio0Tagged Access, Adult, CALR gene, LifeMD, Nordisk, Obesity, semaglutide, Telemedicine, Wegovy

Wegovy, Nordisk, LifeMD, Telemedicine, Access, CALR gene, Obesity, semaglutide, Adult

AbbVie’s Rinvoq cleared for giant cell arteritis in US

2 weeks ago talkbio0Tagged Approved, Giant Cell Arteritis, Inhibitor, Janus kinase, Rinvoq, Steroids, United States Food and Drug Administration, upadacitinib

Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids

Abeona’s $3.1M gene therapy wins FDA nod for rare skin disease

2 weeks ago talkbio0Tagged Abeona, Abeona 's, Approved, Dermatologic disorders, gene therapy, Hallopeau-Siemens Disease, Infrequent, United States Food and Drug Administration, ZEVASKYN

United States Food and Drug Administration, United States Food and Drug Administration, Infrequent, ZEVASKYN, Abeona, gene therapy, Dermatologic disorders, Hallopeau-Siemens Disease, Approved, Abeona ‘s

FDA decision on Stealth’s Barth syndrome drug delayed, again

2 weeks ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Decision, Elamipretide, United States Food and Drug Administration

United States Food and Drug Administration, 3-Methylglutaconic aciduria type 2, Decision, Elamipretide